Browse the corpus

REFERENCES Inamoto H, Ozaki R, Matsuzaki T, et al. Incidence and mortality patterns of malignancy and factors affecting the risk of malignancy in dialysis patients. Nephron 1991; 59:611. Marple JT, MacDougall M. Development of malignancy in the end-stage renal disease patient. Semin Nephrol 1993; 13:306. Buccianti G, Maisonneuve P, Ravasi B, et al. Cancer among patients on renal replacement therapy: a population-based survey in Lombardy, Italy. Int J Cancer 1996; 66:591. Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354:93. Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA 2006; 296:2823. Wong G, Hayen A, Chapman JR, et al. Association of CKD and cancer risk in older people. J Am Soc Nephrol 2009; 20:1341. Stewart JH, Buccianti G, Agodoa L, et al. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol 2003; 14:197. Heidland A, Bahner U, Vamvakas S. Incidence and spectrum of dialysis-associated cancer in three continents. Am J Kidney Dis 2000; 35:347. US Renal Data System: USRDS 2007 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. Am J Kidney Dis 2008; 49(Suppl 1):S1. US Renal Data System: USRDS 2004 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. Am J Kidney Dis 2005; 45(Suppl 1):S1. Port FK, Ragheb NE, Schwartz AG, Hawthorne VM. Neoplasms in dialysis patients: a population-based study. Am J Kidney Dis 1989; 14:119. Holley, JL. Preventive medical screening is not appropriate for many chronic dialysis patients. Semin Dial 2000; 13:369.17. Holley JL. Screening, diagnosis, and treatment of cancer in long-term dialysis patients. Clin J Am Soc Nephrol 2007; 2:604. Chertow GM, Paltiel AD, Owen WF Jr, Lazarus JM. Cost-effectiveness of cancer screening in end-stage renal disease. Arch Intern Med 1996; 156:1345. Kajbaf S, Nichol G, Zimmerman D. Cancer screening and life expectancy of Canadian patients with kidney failure. Nephrol Dial Transplant 2002; 17:1786.

Holley JL. Screening, diagnosis, and treatment of cancer in long-term dialysis patients. Clin J Am Soc Nephrol 2007; 2:604. Chertow GM, Paltiel AD, Owen WF Jr, Lazarus JM. Cost-effectiveness of cancer screening in end-stage renal disease. Arch Intern Med 1996; 156:1345. Kajbaf S, Nichol G, Zimmerman D. Cancer screening and life expectancy of Canadian patients with kidney failure. Nephrol Dial Transplant 2002; 17:1786. LeBrun CJ, Diehl LF, Abbott KC, et al. Life expectancy benefits of cancer screening in the end-stage renal disease population. Am J Kidney Dis 2000; 35:237. Ajam M, Ramanujam LS, Gandhi VC, et al. Colon-cancer screening in dialysis patients. Artif Organs 1990; 14:95. Bini EJ, Kinkhabwala A, Goldfarb DS. Predictive value of a positive fecal occult blood test increases as the severity of CKD worsens. Am J Kidney Dis 2006; 48:580. Morton JJ, Howe SF, Lowell JA, et al. Influence of end-stage renal disease and renal transplantation on serum prostate-specific antigen. Br J Urol 1995; 75:498. Middleton RG. Prostate cancer: are we screening and treating too much? Ann Intern Med 1997; 126:465. Khairullah QT, Pamatmat SD, Chatha M, et al. Early detection of prostate cancer in the ESRD population. Clin Nephrol 2004; 61:308. Smith RA, von Eschenbach AC, Wender R, et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001--testing for early lung cancer detection. CA Cancer J Clin 2001; 51:38. Taneja S, Mandayam S, Kayani ZZ, et al. Comparison of stage at diagnosis of cancer in patients who are on dialysis versus the general population. Clin J Am Soc Nephrol 2007; 2:1008. Crosbie EJ, Kitchener HC. Human papillomavirus in cervical screening and vaccination. Clin Sci (Lond) 2006; 110:543. Ault KA. Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: a review. Obstet Gynecol Surv 2006; 61:S26. Holley JL, Von Roenn J. Screening for breast cancer in women with CKD stages 4 to 5. Am J Kidney Dis 2010; 56:820. Castellanos M, Varma S, Ahern K, et al. Increased breast calcifications in women with ESRD on dialysis: implications for breast cancer screening. Am J Kidney Dis 2006; 48:301. Filella X, Cases A, Molina R, et al. Tumor markers in patients with chronic renal failure. Int J Biol Markers 1990; 5:85.

Holley JL, Von Roenn J. Screening for breast cancer in women with CKD stages 4 to 5. Am J Kidney Dis 2010; 56:820. Castellanos M, Varma S, Ahern K, et al. Increased breast calcifications in women with ESRD on dialysis: implications for breast cancer screening. Am J Kidney Dis 2006; 48:301. Filella X, Cases A, Molina R, et al. Tumor markers in patients with chronic renal failure. Int J Biol Markers 1990; 5:85. Lye WC, Tambyah P, Leong SO, Lee EJ. Serum tumor markers in patients on dialysis and kidney transplantation. Adv Perit Dial 1994; 10:109. Docci D, Pistocchi E, Turci F, et al. Serum CA 19-9 and CA 50 antigens in hemodialysis patients. Clin Nephrol 1987; 27:179. Bastani B, Chu N. Serum CA-125 level in end-stage renal disease patients maintained on chronic peritoneal dialysis or hemodialysis: the effect of continuous presence of peritoneal fluid, peritonitis, and peritoneal catheter implantation. Am J Nephrol 1995; 15:468. Ho-dac-Pannekeet MM, Hiralall JK, Struijk DG, Krediet RT. Longitudinal follow-up of CA125 in peritoneal effluent. Kidney Int 1997; 51:888. Topic 1946 Version 6.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [0504-118.195.65.248-6BEDC4A8C2-S244013.14]